Maat Pharma SA Cash Flow-to-Debt Ratio
Maat Pharma SA cash flow-to-debt ratio. Maat Pharma SA (MAAT) has a Cash Flow-to-Debt Ratio of -0.38x as of June 2025, meaning its operating cash flow of €-15.37 Million could theoretically repay 0% of its total liabilities (€40.58 Million) in one year. See financial agility of Maat Pharma SA to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Maat Pharma SA (2017–2024)
Cash flow-to-debt ratio of Maat Pharma SA from 2017 to 2024. Historical debt coverage capacity for Maat Pharma SA across 8 annual periods. Also explore MAAT shareholders equity momentum to track the company's year-over-year net asset growth rate.
Maat Pharma SA Cash Flow-to-Debt Ratio by Year (2017–2024)
Maat Pharma SA cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Maat Pharma SA. For the full cash flow conversion analysis, see MAAT operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.78x | €-22.04 Million | €28.16 Million | ▲ +5.8% |
| 2023 | -0.83x | €-18.67 Million | €22.46 Million | ▼ -18.1% |
| 2022 | -0.70x | €-12.61 Million | €17.91 Million | ▲ +15.1% |
| 2021 | -0.83x | €-7.93 Million | €9.56 Million | ▼ -18.9% |
| 2020 | -0.70x | €-5.81 Million | €8.34 Million | ▼ -76.9% |
| 2019 | -0.39x | €-5.02 Million | €12.73 Million | ▲ +53.0% |
| 2018 | -0.84x | €-3.87 Million | €4.62 Million | ▲ +13.5% |
| 2017 | -0.97x | €-3.87 Million | €3.99 Million | — |